Last reviewed · How we verify
Ronapreve (CASIRIVIMAB)
Ronapreve (generic name: CASIRIVIMAB) is a Monoclonal antibody drug developed by Regeneron Pharmaceuticals, Inc.. It is currently FDA-approved (first approved 2020) for COVID-19.
Ronapreve (Casirivimab) is a monoclonal antibody developed by Regeneron Pharmaceuticals, Inc. It is used to treat COVID-19 and works by binding to the SARS-CoV-2 virus, preventing it from entering host cells. Ronapreve is a patented medication with FDA approval since 2020. Key safety considerations include potential allergic reactions and the risk of transmission of COVID-19 despite treatment. As a monoclonal antibody, Ronapreve is a large molecule, not a small molecule.
At a glance
| Generic name | CASIRIVIMAB |
|---|---|
| Sponsor | Regeneron Pharmaceuticals, Inc. |
| Modality | Monoclonal antibody |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
- COVID-19
Common side effects
Key clinical trials
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
- COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease (PHASE1,PHASE2)
- A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults (PHASE3)
- COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age (PHASE2)
- COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers (PHASE2)
- COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19 (PHASE1)
- COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ronapreve CI brief — competitive landscape report
- Ronapreve updates RSS · CI watch RSS
- Regeneron Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Ronapreve
What is Ronapreve?
What is Ronapreve used for?
Who makes Ronapreve?
What is the generic name of Ronapreve?
When was Ronapreve approved?
What development phase is Ronapreve in?
Related
- Manufacturer: Regeneron Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for COVID-19
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing